RSS

SHARE

FOLLOW

Coenzima Q10

1. Ernster L, Dallner G. Biochemical, physiological and medical aspects of ubiquinone function. Biochim Biophys Acta. 1995; 1271(1):195–204.

 

2. Crane FL. Biochemical functions of coenzyme Q10. J Am Coll Nutr. 2001; 20(6):591–598.

 

3. Nohl H, Gille L. The role of coenzyme Q in lysosomes. In: Kagan VEQ, P. J. (ed). Coenzyme Q: Molecular Mechanisms in Health and Disease. Boca Raton: CRC Press; 2001:99–106.

 

4. Thomas SR, Stocker R. Mechanisms of antioxidant action of ubiquinol-10 for low-density lipoprotein. In: Kagan VE, Quinn PJ,eds. Coenzyme Q: Molecular Mechanisms in Health and Disease. Boca Raton: CRC Press; 2001:131–150.

 

5. Beckman KB, Ames BN. Mitochondrial aging: open questions. Ann N Y Acad Sci. 1998; 854:118–127.

 

6. Kalen A, Appelkvist EL, Dallner G. Age-related changes in the lipid compositions of rat and human tissues. Lipids. 1989; 24(7):579–584.

 

7. Alho H, Lonnrot K. Coenzyme Q supplementation and longevity. In: Kagan VE, Quinn PJ,eds. Coenzyme Q: Molecular Mechanisms in Health and Disease. Boca Raton: CRC Press; 2001:371–380.

 

8. Quiles JL, Ochoa JJ, Battino M, et al. Life-long supplementation with a low dosage of coenzyme Q10 in the rat: effects on antioxidant status and DNA damage. Biofactors. 2005; 25(1-4):73–86.

 

9. Mohr D, Bowry VW, Stocker R. Dietary supplementation with coenzyme Q10 results in increased levels of ubiquinol-10 within circulating lipoproteins and increased resistance of human low-density lipoprotein to the initiation of lipid peroxidation. Biochim Biophys Acta. 1992; 1126(3):247–254.

 

10. Witting PK, Pettersson K, Letters J, Stocker R. Anti-atherogenic effect of coenzyme Q10 in apolipoprotein E gene knockout mice. Free Radic Biol Med. 2000; 29(3-4):295–305.

 

11. Thomas SR, Leichtweis SB, Pettersson K, et al. Dietary cosupplementation with vitamin E and coenzyme Q(10) inhibits atherosclerosis in apolipoprotein E gene knockout mice. Arterioscler Thromb Vasc Biol. 2001; 21(4):585–593.

 

12. Shoffner JM. Oxidative phosphorylation diseases. In: Scriver CR, Beaudet AL, Sly WS, Valle D,eds. The metabolic and molecular bases of inherited disease. 8th ed. Volume 2. New York: McGraw-Hill; 2001:2367–2392.

 

13. Munnich A, Rotig A, Cormier-Daire V, Rustin P. Clinical presentation of respiratory chain deficiency. In: Scriver CR, Beaudet AL, Sly WS, Valle D,eds. The metabolic and molecular bases of inherited disease. 8th ed. Volume 2. New York: McGraw-Hill; 2001:2261–2274.

 

14. Folkers K, Vadhanavikit S, Mortensen SA. Biochemical rationale and myocardial tissue data on the effective therapy of cardiomyopathy with coenzyme Q10. Proc Natl Acad Sci U S A. 1985; 82(3):901–904.

 

15. Belardinelli R, Mucaj A, Lacalaprice F, et al. Coenzyme Q10 and exercise training in chronic heart failure. Eur Heart J. 2006.

 

16. Tran MT, Mitchell TM, Kennedy DT, Giles JT. Role of coenzyme Q10 in chronic heart failure, angina, and hypertension. Pharmacotherapy. 2001; 21(7):797–806.

 

17. Belardinelli R, Mucaj A, Lacalaprice F, et al. Coenzyme Q10 improves contractility of dysfunctional myocardium in chronic heart failure. Biofactors. 2005; 25(1–4):137–145.

 

18. Khatta M, Alexander BS, Krichten CM, et al. The effect of coenzyme Q10 in patients with congestive heart failure. Ann Intern Med. 2000; 132(8):636–640.

 

19. Watson PS, Scalia GM, Galbraith A, Burstow DJ, Bett N, Aroney CN. Lack of effect of coenzyme Q on left ventricular function in patients with congestive heart failure. J Am Coll Cardiol. 1999; 33(6):1549–1552.

 

20.   Sander S. et al. The impact of coenzyme Q10 on systolic function in patients with chronic heart failure. J Card Fail, 2006; 12:464–472.

 

21.   Pepe S. et al. Coenzyme Q10 in cardiovascular disease. Mitochondrion, 2007; 7:154–167.

 

22. Lonnrot K, Tolvanen JP, Porsti I, Ahola T, Hervonen A, Alho H. Coenzyme Q10 supplementation and recovery from ischemia in senescent rat myocardium. Life Sci. 1999; 64(5):315–323.

 

23. Maulik N, Yoshida T, Engelman RM, Bagchi D, Otani H, Das DK. Dietary coenzyme Q(10) supplement renders swine hearts resistant to ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol. 2000; 278(4):H1084–1090.

 

24. Rosenfeldt FL, Pepe S, Linnane A, et al. The effects of ageing on the response to cardiac surgery: protective strategies for the ageing myocardium. Biogerontology. 2002; 3(1–2):37–40.

 

25. Langsjoen PH, Langsjoen AM. Overview of the use of CoQ10 in cardiovascular disease. Biofactors. 1999; 9(2–4):273–284.

 

26. Taggart DP, Jenkins M, Hooper J, et al. Effects of short-term supplementation with coenzyme Q10 on myocardial protection during cardiac operations. Ann Thorac Surg. 1996; 61(3):829–833.

 

27. Singh RB, Niaz MA, Rastogi SS, Shukla PK, Thakur AS. Effect of hydrosoluble coenzyme Q10 on blood pressures and insulin resistance in hypertensive patients with coronary artery disease. J Hum Hypertens. 1999; 13(3):203–208.

 

28. Burke BE, Neuenschwander R, Olson RD. Randomized, double-blind, placebo-controlled trial of coenzyme Q10 in isolated systolic hypertension. South Med J. 2001; 94(11):1112–1117.

 

29. Rosenfeldt F. L. et al. Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials. Journal of Human Hypertension, 2007; 21:297–306.

 

30. Ross R. Atherosclerosis – an inflammatory disease. N Engl J Med. 1999; 340(2):115–126.

 

31. Watts GF, Playford DA, Croft KD, Ward NC, Mori TA, Burke V. Coenzyme Q(10) improves endothelial dysfunction of the brachial artery in Type II diabetes mellitus. Diabetologia. 2002; 45(3):420–426.

 

32. Raitakari OT, McCredie RJ, Witting P, et al. Coenzyme Q improves LDL resistance to ex vivo oxidation but does not enhance endothelial function in hypercholesterolemic young adults. Free Radic Biol Med. 2000; 28(7):1100–1105.

 

33. Kuettner A, Pieper A, Koch J, Enzmann F, Schroeder S. Influence of coenzyme Q(10) and cerivastatin on the flow-mediated vasodilation of the brachial artery: results of the ENDOTACT study. Int J Cardiol. 2005; 98(3):413–419.

 

34. McDonnell MG, Archbold GP. Plasma ubiquinol/cholesterol ratios in patients with hyperlipidaemia, those with diabetes mellitus and in patients requiring dialysis. Clin Chim Acta. 1996; 253(1–2):117–126.

 

35. Henriksen JE, Andersen CB, Hother-Nielsen O, Vaag A, Mortensen SA, Beck-Nielsen H. Impact of ubiquinone (coenzyme Q10) treatment on glycaemic control, insulin requirement and well-being in patients with Type 1 diabetes mellitus. Diabet Med. 1999; 16(4):312–318.

 

36. Eriksson JG, Forsen TJ, Mortensen SA, Rohde M. The effect of coenzyme Q10 administration on metabolic control in patients with type 2 diabetes mellitus. Biofactors. 1999; 9(2–4):315–318.

 

37. Gotz ME, Gerstner A, Harth R, et al. Altered redox state of platelet coenzyme Q10 in Parkinson's disease. J Neural Transm. 2000; 107(1):41–48.

 

38. Shults CW, Haas RH, Passov D, Beal MF. Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects. Ann Neurol. 1997; 42(2):261–264.

 

39. Shults CW, Oakes D, Kieburtz K, et al. Effects of coenzyme q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol. 2002; 59(10):1541–1550.

 

40. Muller T, Buttner T, Gholipour AF, Kuhn W. Coenzyme Q10 supplementation provides mild symptomatic benefit in patients with Parkinson's disease. Neurosci Lett. 2003; 341(3):201–204.

 

41. Koroshetz WJ, Jenkins BG, Rosen BR, Beal MF. Energy metabolism defects in Huntington's disease and effects of coenzyme Q10. Ann Neurol. 1997; 41(2):160–165.

 

42. Beal MF. Coenzyme Q10 as a possible treatment for neurodegenerative diseases. Free Radic Res. 2002; 36(4):455–460.

 

43. Ferrante RJ, Andreassen OA, Dedeoglu A, et al. Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease. J Neurosci. 2002; 22(5):1592–1599.

 

44. Schilling G, Coonfield ML, Ross CA, Borchelt DR. Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington's disease transgenic mouse model. Neurosci Lett. 2001; 315(3):149–153.

 

45. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology. 2001; 57(3):397–404.

 

46. Folkers K, Osterborg A, Nylander M, Morita M, Mellstedt H. Activities of vitamin Q10 in animal models and a serious deficiency in patients with cancer. Biochem Biophys Res Commun. 1997; 234(2):296–299.

 

47. Hodges S, Hertz N, Lockwood K, Lister R. CoQ10: could it have a role in cancer management? Biofactors. 1999; 9(2–4):365–370.

 

48. Hanioka T, Tanaka M, Ojima M, Shizukuishi S, Folkers K. Effect of topical application of coenzyme Q10 on adult periodontitis. Mol Aspects Med. 1994; 15 Suppl:s241–248.

 

49. Weston SB, Zhou S, Weatherby RP, Robson SJ. Does exogenous coenzyme Q10 affect aerobic capacity in endurance athletes? Int J Sport Nutr. 1997; 7(3):197–206.

 

50. Porter DA, Costill DL, Zachwieja JJ, et al. The effect of oral coenzyme Q10 on the exercise tolerance of middle-aged, untrained men. Int J Sports Med. 1995; 16(7):421–427.

 

51. Braun B, Clarkson PM, Freedson PS, Kohl RL. Effects of coenzyme Q10 supplementation on exercise performance, VO2max, and lipid peroxidation in trained cyclists. Int J Sport Nutr. 1991; 1(4):353–365.

 

52. Laaksonen R, Fogelholm M, Himberg JJ, Laakso J, Salorinne Y. Ubiquinone supplementation and exercise capacity in trained young and older men. Eur J Appl Physiol Occup Physiol. 1995; 72(1–2):95–100.

 

53. Malm C, Svensson M, Ekblom B, Sjodin B. Effects of ubiquinone-10 supplementation and high intensity training on physical performance in humans. Acta Physiol Scand. 1997; 161(3):379–384.

 

54. Folkers K, Langsjoen P, Nara Y, et al. Biochemical deficiencies of coenzyme Q10 in HIV infection and exploratory treatment. Biochem Biophys Res Commun. 1988; 153:888–896.

 

55. Khan M, Gross J, Haupt H, et al., A pilot clinical trial of the effects of coenzyme Q10 on chronic tinnitus aurium. Otolaryngol Head Neck Surg. 2007; 136(1):72–7.

 

56. Hoppe U, Bergemann J, Diembeck W, et al. Coenzyme Q10, a cutaneous antioxidant and energizer. Biofactors. 1999; 9(2–4):371–8.

 

57. Weber C. Dietary intake and absorption of coenzyme Q. In: Kagan VE, Quinn PJ,eds. Coenzyme Q: Molecular Mechanisms in Health and Disease. Boca Raton: CRC Press; 2001:209–215.

 

58. Overvad K, Diamant B, Holm L, Holmer G, Mortensen SA, Stender S. Coenzyme Q10 in health and disease. Eur J Clin Nutr. 1999; 53(10):764–770.

 

59. Kamei M, Fujita T, Kanbe T, Sakaki K, Oshiba K, Otani S, Matsui-Yuasa I, Morisawa S: The distribution and content of ubiquinone in foods. Internat. J. Vit. Nutr. Res., 56, 57–63,1986.

 

60. Hallström H: Oskadlighetsbedömning av coenzyme Q10. Vår Föda 46: 250–259, 1993.

 

61. Willis R, Anthony M, Sun L, Honse Y, Qiao G. Clinical implications of the correlation between coenzyme Q10 and vitamin B6 status. Biofactors. 1999; 9(2–4):359–363.

 

62. Singh RB, Niaz MA, Kumar A, Sindberg CD, Moesgaard S, Littarru GP. Effect on absorption and oxidative stress of different oral Coenzyme Q10 dosages and intake strategy in healthy men. Biofactors. 2005; 25(1–4):219–224.

 

63. Hendler SS, Rorvik DR (eds). PDR for Nutritional Supplements. Montvale: Medical Economics Company, Inc; 2001.